

## Special Issue

# The Critical Role of Adjuvants in Modern Vaccinology

### Message from the Guest Editor

There is a lack of safe and effective adjuvants to support the development of new and improved vaccines. Often, different types of adjuvants are necessary to induce optimal immune responses for specific diseases, and adjuvants may need to be tailored to specific age groups. Historically, the development of adjuvants has relied mainly on empirical experience, with only a handful of adjuvants approved for human use since the first, Alum, was discovered over 90 years ago. However, substantial advances have been made over the last three decades in our understanding of how adjuvants function. This Special Issue will include commentaries, original research articles, and reviews related to the discovery and development of adjuvants for various types of vaccines, such as subunit and mRNA-based vaccines to combat infectious diseases, cancer, and immune-mediated diseases. Additionally, we welcome studies on the mechanisms of adjuvants and investigations into the development of combinatorial adjuvants for vaccine applications.

---

### Guest Editor

Dr. Xinyuan Chen

Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA

---

### Deadline for manuscript submissions

15 August 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/261653](https://mdpi.com/si/261653)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).